# Efficacy and Safety Study of Benralizumab in Patient With Eosinophilic Chronic Rhinosinusitis With Nasal Polyps (ORCHID)

> **NCT04157335** · PHASE3 · TERMINATED · sponsor: **AstraZeneca** · enrollment: 295 (actual)

## Conditions studied

- Nasal Polyposis
- Eosinophilic Chronic Rhinosinusitis

## Interventions

- **BIOLOGICAL:** Benralizumab 30 mg
- **BIOLOGICAL:** Matched placebo

## Key facts

- **NCT ID:** NCT04157335
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-11-25
- **Primary completion:** 2024-08-06
- **Final completion:** 2025-04-07
- **Target enrollment:** 295 (ACTUAL)
- **Why stopped:** The study has a double-blind period and an open-label period. The study did not meet its primary endpoints after the primary LSLV and the decision was taken to terminate the study early.
- **Last updated:** 2026-02-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04157335

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04157335, "Efficacy and Safety Study of Benralizumab in Patient With Eosinophilic Chronic Rhinosinusitis With Nasal Polyps (ORCHID)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04157335. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*